5-Amino-1MQ (small-molecule NNMT inhibitor)

Also referred to as 5-amino-1-methylquinolinium.

Status: Investigational. 5-Amino-1MQ is not an FDA-approved drug product and has no approved indication. It is not listed in DailyMed. It is worth stating plainly that it is a small-molecule chemical, not a peptide, which matters because it is manufactured, studied, and regulated differently from peptide research compounds, even though it is often marketed alongside them.

5-Amino-1MQ is a synthetic small molecule studied as an inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase), which sits at a crossroads of cellular energy metabolism. It is frequently sold alongside peptides in research-chemical marketplaces, but chemically it is not a peptide at all, and that distinction affects how it is manufactured, analyzed, and regulated. Research to date is almost entirely limited to cultured cells and rodents. No published human trial data establish safety or benefit in people.

What it is

5-Amino-1MQ is a small organic molecule, structurally a quinolinium derivative, that inhibits NNMT enzymatic activity. Unlike a peptide, it is not built from a chain of amino acids and does not degrade the way peptides do, which changes its stability, oral bioavailability discussions in animal work, and how a chemist would characterize its purity. It is commonly grouped with peptide products in online marketplaces, a categorization that is chemically inaccurate and can obscure how differently it is studied and regulated.

Why people ask about it

Interest in 5-Amino-1MQ tends to come from its proposed role in adipocyte metabolism and NAD+-related pathways, both frequent topics in longevity and body-composition discussions. Patients sometimes assume that because it is discussed near peptides like MOTS-c, it shares a similar evidence base or regulatory posture, when in fact the underlying chemistry and research literature are distinct. Clarifying that distinction is part of giving patients an accurate picture before they consider any research substance.

Proposed mechanism

NNMT is an enzyme involved in methylation reactions that influence cellular NAD+ and SAM availability, both central to energy metabolism. In cell and rodent models, inhibiting NNMT with 5-Amino-1MQ has been proposed to shift adipocyte metabolism toward increased energy expenditure and reduced fat accumulation. This mechanism is derived from laboratory and animal experiments and has not been confirmed as clinically meaningful in humans, where NNMT biology is more complex and tissue-specific.

What researchers have studied

• NNMT inhibition and its downstream effects on cultured adipocytes
• Body weight and fat mass changes in diet-induced obese mice
• NAD+ and SAM metabolite changes in animal tissue after administration
• Structure-activity relationships among NNMT inhibitor candidates in chemistry literature
• Basic pharmacokinetic characterization in rodents

Human evidence

• No published human clinical trials of 5-Amino-1MQ were identified.
• There is no established human dosing, exposure, or pharmacokinetic profile because no such study has been conducted or published.
• All efficacy signals to date come from mouse models of obesity, which frequently do not replicate in human metabolic disease.
• There is no human safety database, meaning rare or long-term adverse effects in people are entirely unknown.

Preclinical evidence

• Diet-induced obese mice given 5-Amino-1MQ show reduced weight gain and fat mass in published rodent studies (animal work).
• Cultured adipocyte experiments describe NNMT inhibition altering lipid metabolism markers (cell work).
• Rodent studies report changes in muscle and liver metabolic markers following administration (animal work).
• Early medicinal chemistry papers describe the compound's selectivity for NNMT relative to other methyltransferases (chemistry/cell work).

What is not yet known

• Whether NNMT inhibition produces a comparable metabolic effect in human tissue as it does in mouse models.
• What an appropriate, safe human exposure would be, since this has never been formally studied.
• Long-term safety, including any effects on methylation-dependent processes elsewhere in the body.
• Purity, accuracy of labeling, and manufacturing consistency of product sold outside regulated pharmaceutical channels.
• How it might interact with metabolic medications or supplements affecting NAD+ pathways.
• Whether marketing 5-Amino-1MQ as similar to peptide products misleads patients about its evidence base or regulatory category.

Regulatory status and access

Compounding is never approval, and 5-Amino-1MQ is not something GOAL.MD compounds, dispenses, or recommends for use outside of research. Ask about current availability. Only a physician can determine whether discussing this substance is appropriate for a given patient, and that determination follows an individualized evaluation.

Known and potential risks

• Complete absence of human safety data means unknown risks cannot be excluded.
• As a small molecule sold in research-chemical channels, product quality, purity, and accurate labeling are not independently verified.
• Methylation pathway modulation touches multiple cellular processes, and off-target effects in humans have not been characterized.
• Self-sourced use without physician oversight removes the ability to identify adverse reactions early.
• Marketing that groups it with peptides may create a false impression of a shared, more established evidence base.
• Interaction risk with other metabolic or NAD-precursor supplements is entirely unstudied.

Cautions and who may not be a candidate

• Pregnancy and breastfeeding, given no human safety data of any kind.
• Personal or strong family history of malignancy, since methylation pathway effects on cell growth signalling have not been ruled out in humans.
• Undiagnosed metabolic symptoms, which merit standard medical evaluation rather than an unproven research chemical.
• Concurrent use of other experimental metabolic compounds without physician coordination.
• Known hypersensitivity to quinolinium-derived compounds or related chemical structures.
• Any expectation that this substance can substitute for established weight or metabolic management.

Questions to discuss with a physician

• How does the fact that this is a small molecule, not a peptide, change how it would be evaluated or regulated?
• What established, evidence-based options exist for the metabolic outcome I'm interested in?
• What would you look for as early warning signs if this were ever discussed in a research context?
• How is NNMT biology different between rodents and humans, and does that matter here?
• What questions should I ask about the sourcing and testing of any research chemical?
• What evidence would need to exist before this could be considered part of standard care?

Frequently asked questions

Is 5-Amino-1MQ FDA-approved?

No. It is not an FDA-approved drug product and has no approved indication. It is studied only in laboratory and animal research settings.

Is 5-Amino-1MQ a peptide?

No. It is a small organic molecule, not a chain of amino acids, even though it is frequently marketed alongside peptide research compounds. That chemical distinction affects how it is manufactured and studied.

Does GOAL.MD sell 5-Amino-1MQ?

This page is educational only. It summarizes published research and does not represent an offer, prescription, or sale.

What is NNMT and why does it matter here?

NNMT is an enzyme involved in cellular methylation reactions tied to energy metabolism. 5-Amino-1MQ is studied as an inhibitor of this enzyme, primarily in cell and rodent experiments.

Has 5-Amino-1MQ been tested in people?

No published human clinical trials were identified. All efficacy data to date come from cultured cells and mouse models.

Can 5-Amino-1MQ help with fat loss?

There is no human evidence to support that. Reduced fat mass has been reported in mouse studies, which do not reliably predict effects in humans.

Is it risky to buy 5-Amino-1MQ from research-chemical sellers?

Yes, in the sense that purity, labeling accuracy, and manufacturing quality are not independently verified in that market, and there is no human safety data to fall back on.

Why is it often sold next to peptides?

Marketplaces group substances by their research or longevity positioning rather than by chemical class, which can blur the fact that 5-Amino-1MQ is chemically and regulatorily distinct from a peptide.

Are there known drug interactions?

Interactions with other metabolic medications or NAD-precursor supplements have not been studied in humans, so none can be ruled in or out with confidence.

What would it take for this to become an evidence-based option?

Controlled human trials demonstrating safety and a defined, reproducible benefit would be required. None have been published as of this writing.

What is 5-Amino-1MQ?

5-Amino-1MQ is a small organic molecule, structurally a quinolinium derivative, that inhibits NNMT enzymatic activity. Unlike a peptide, it is not built from a chain of amino acids and does not degrade the way peptides do, which changes its stability, oral bioavailability discussions in animal work, and how a chemist would characterize its purity. It is commonly grouped with peptide products in online marketplaces, a categorization that is chemically inaccurate and can obscure how differently it is studied and regulated.

Does the legal or regulatory status of 5-Amino-1MQ tell me whether it works?

No. Regulatory status describes what may lawfully be made, prescribed, or sold, and it is a separate question from what the research shows. On this page the regulatory description and the evidence tiers are kept apart so neither is mistaken for the other.

Can a licensed U.S. compounding pharmacy prepare 5-Amino-1MQ?

Compounding is never approval, and 5-Amino-1MQ is not something GOAL. MD compounds, dispenses, or recommends for use outside of research.

What human evidence exists for 5-Amino-1MQ?

No published controlled human trials were identified for the uses discussed here. No published human clinical trials of 5-Amino-1MQ were identified.

Have there been controlled human trials of 5-Amino-1MQ?

No adequately controlled human trial for the uses discussed here was identified. Anything presented elsewhere as a human result is an extrapolation from laboratory or animal work, or an anecdote.

What have animal and laboratory studies of 5-Amino-1MQ reported?

Diet-induced obese mice given 5-Amino-1MQ show reduced weight gain and fat mass in published rodent studies (animal work); Cultured adipocyte experiments describe NNMT inhibition altering lipid metabolism markers (cell work); Rodent studies report changes in muscle and liver metabolic markers following administration (animal work). These are animal, tissue, or cell-culture findings. They describe a model, not a demonstrated result in people.

Do the animal findings for 5-Amino-1MQ mean it works in people?

No. Findings in animals or in cell culture routinely fail to reproduce in humans, and a positive laboratory model is not evidence of a human benefit. Whether any of this translates to people is exactly what has not been established.

How is 5-Amino-1MQ proposed to work?

NNMT is an enzyme involved in methylation reactions that influence cellular NAD+ and SAM availability, both central to energy metabolism. In cell and rodent models, inhibiting NNMT with 5-Amino-1MQ has been proposed to shift adipocyte metabolism toward increased energy expenditure and reduced fat accumulation. This is a proposed pathway rather than a demonstrated effect.

What is 5-Amino-1MQ being studied for?

Published work has focused on NNMT inhibition and its downstream effects on cultured adipocytes; Body weight and fat mass changes in diet-induced obese mice; NAD+ and SAM metabolite changes in animal tissue after administration; Structure-activity relationships among NNMT inhibitor candidates in chemistry literature. A research focus describes where questions are being asked, not where answers have been found.

What is still unknown about 5-Amino-1MQ?

Whether NNMT inhibition produces a comparable metabolic effect in human tissue as it does in mouse models; What an appropriate, safe human exposure would be, since this has never been formally studied; Long-term safety, including any effects on methylation-dependent processes elsewhere in the body; Purity, accuracy of labeling, and manufacturing consistency of product sold outside regulated pharmaceutical channels.

What are the risks of 5-Amino-1MQ?

Complete absence of human safety data means unknown risks cannot be excluded; As a small molecule sold in research-chemical channels, product quality, purity, and accurate labeling are not independently verified; Methylation pathway modulation touches multiple cellular processes, and off-target effects in humans have not been characterized.

Who should not consider 5-Amino-1MQ?

A physician would generally consider it inappropriate in these situations without specialist input: Pregnancy and breastfeeding, given no human safety data of any kind; Personal or strong family history of malignancy, since methylation pathway effects on cell growth signalling have not been ruled out in humans; Undiagnosed metabolic symptoms, which merit standard medical evaluation rather than an unproven research chemical; Concurrent use of other experimental metabolic compounds without physician coordination.

Is 5-Amino-1MQ appropriate during pregnancy or breastfeeding?

No. Pregnancy and breastfeeding are listed as situations where this is not appropriate, because the safety data needed to make that judgement in those populations does not exist.

How does 5-Amino-1MQ interact with other medications?

Interaction behaviour in people is not characterised for this substance, which is itself a reason a physician reviews the full medication list before any discussion. Interaction risk with other metabolic or NAD-precursor supplements is entirely unstudied.

What would a physician monitor if 5-Amino-1MQ were discussed?

Monitoring concepts include General metabolic panel monitoring is a standard concept in any physician-guided discussion of metabolic health; Clinical follow-up for unexpected symptoms is a baseline expectation for any unregulated research substance; No validated monitoring protocol specific to 5-Amino-1MQ exists, so any oversight would be conservative and individualized. These are concepts a clinician would apply, not instructions for self-directed use.

Are products sold online as 5-Amino-1MQ verified?

No. As a small molecule sold in research-chemical channels, product quality, purity, and accurate labeling are not independently verified. Material bought outside a licensed pharmacy has no verified identity, purity, or sterility.

How would a GOAL.MD physician evaluate a question about 5-Amino-1MQ?

A physician starts with the problem you are trying to solve, reviews your history and current medications, and says plainly where the evidence stands. Medical appropriateness is determined only after a full evaluation, and for many substances the honest answer is that the evidence does not support use.

What should I ask a physician about 5-Amino-1MQ?

Useful questions include: How does the fact that this is a small molecule, not a peptide, change how it would be evaluated or regulated?; What established, evidence-based options exist for the metabolic outcome I'm interested in?; What would you look for as early warning signs if this were ever discussed in a research context?; How is NNMT biology different between rodents and humans, and does that matter here?.

Why do people ask about 5-Amino-1MQ?

Interest in 5-Amino-1MQ tends to come from its proposed role in adipocyte metabolism and NAD+-related pathways, both frequent topics in longevity and body-composition discussions. Patients sometimes assume that because it is discussed near peptides like MOTS-c, it shares a similar evidence base or regulatory posture, when in fact the underlying chemistry and research literature are distinct.

Who reviews what GOAL.MD publishes about 5-Amino-1MQ?

Clinical content is reviewed by a named physician for medical accuracy and by a second physician for regulatory and compliance language before it is published, and a review byline appears only when that review is recorded. New material stays unpublished until both reviews are on record.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.